Clincosm LogoSign in Get a demo

Renal Cell Carcinoma

Showing NaN - NaN of 65
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Renal Cell Carcinoma Trial in Houston (Tivozanib, Nivolumab)

Not yet recruiting
  • Renal Cell Carcinoma
  • Houston, Texas
    M D Anderson Cancer Center
Sep 19, 2023

Renal Cell Carcinoma, Nasopharyngeal Carcinoma, Non Hodgkin Lymphoma Trial in United States (PRO1160)

Not yet recruiting
  • Renal Cell Carcinoma
  • +2 more
  • Detroit, Michigan
  • +4 more
Jan 31, 2023

Renal Cell Carcinoma Trial in Worldwide (Atezolizumab, Placebo)

Completed
  • Renal Cell Carcinoma
  • Scottsdale, Arizona
  • +185 more
Jan 30, 2023

Advanced Solid Tumors, Lymphoma, Gastric Cancer Trial in United States (FT500, Nivolumab, Pembrolizumab)

Completed
  • Advanced Solid Tumors
  • +17 more
  • San Diego, California
  • +3 more
Jan 27, 2023

Metastatic Solid Tumors, NSCLC, Melanoma Trial in United States (INBRX-105 - PDL1x41BB antibody, Pembrolizumab)

Recruiting
  • Metastatic Solid Tumors
  • +7 more
  • Scottsdale, Arizona
  • +12 more
Jan 26, 2023

Gastric Cancer, Renal Cell Carcinoma, Melanoma Trial in United States (HFB200301)

Recruiting
  • Gastric Cancer
  • +8 more
  • Scottsdale, Arizona
  • +9 more
Dec 22, 2022

Colorectal Cancer, NSCLC, Triple Negative Breast Cancer Trial in Spain, United Kingdom, United States (GEN1029

Terminated
Has Results
  • Colorectal Cancer
  • +6 more
  • GEN1029 (HexaBody®-DR5/DR5)
  • New Haven, Connecticut
  • +5 more
Nov 11, 2022

Renal Cell Carcinoma Trial in Houston (Perfusion CT scan)

Active, not recruiting
  • Renal Cell Carcinoma
  • Perfusion CT scan
  • Houston, Texas
    University of Texas MD Anderson Cancer Center
Dec 6, 2022

Melanoma, Breast Carcinoma, Hepatocellular Carcinoma Trial in United States (XmAb20717)

Completed
  • Melanoma
  • +27 more
  • XmAb20717
  • Los Angeles, California
  • +16 more
Nov 29, 2022

Renal Cell Carcinoma Trial in Worldwide (Nivolumab, Bempegaldesleukin, Axitinib)

Active, not recruiting
  • Renal Cell Carcinoma
  • Nivolumab
  • +2 more
  • Springdale, Arkansas
  • +33 more
Nov 22, 2022

Melanoma, Prostate Cancer, Ovarian Cancer Trial in United States (Pegilodecakin, Paclitaxel or Docetaxel and Carboplatin or

Active, not recruiting
  • Melanoma
  • +8 more
  • Los Angeles, California
  • +9 more
Nov 15, 2022

Squamous Cell Carcinoma of Head and Neck, NSCLC, Hepatocellular Carcinoma Trial in Worldwide (KY1044, KY1044 and atezolizumab)

Recruiting
  • Squamous Cell Carcinoma of Head and Neck
  • +11 more
  • New Haven, Connecticut
  • +12 more
Nov 3, 2022

Breast Cancer, Ovarian Cancer, Non Small Cell Lung Cancer Trial in San Francisco, Denver, San Antonio (P-MUC1C-ALLO1 CAR-T

Recruiting
  • Breast Cancer
  • +8 more
  • San Francisco, California
  • +4 more
Oct 26, 2022

Renal Cell Carcinoma Trial in Houston (Sunitinib, Nephrectomy)

Active, not recruiting
  • Renal Cell Carcinoma
  • Houston, Texas
  • +1 more
Oct 11, 2022

Non-small-cell Lung Cancer, Squamous Cell Carcinoma of the Head and Neck, Renal Cell Carcinoma Trial in United States

Active, not recruiting
  • Non-small-cell Lung Cancer
  • +5 more
  • PF-07209960
  • Duarte, California
  • +11 more
Oct 10, 2022

Melanoma, NSCLC, Breast Cancer Trial in United States (CDX-1140, CDX-301, Pembrolizumab)

Completed
  • Melanoma
  • +25 more
  • Scottsdale, Arizona
  • +10 more
Sep 27, 2022

Study of Kidney Tumors in Younger Patients

Recruiting
  • Adult Cystic Nephroma
  • +24 more
  • Cytology Specimen Collection Procedure
  • Laboratory Biomarker Analysis
  • Birmingham, Alabama
  • +247 more
Sep 2, 2022

Breast Cancer, Cholangiocarcinoma, Colorectal Cancer Trial in Worldwide (Entrectinib)

Recruiting
  • Breast Cancer
  • +15 more
  • Goodyear, Arizona
  • +146 more
Aug 24, 2022

Tumor Malignant, Renal Cell Carcinoma, Hormone Receptor Positive Breast Carcinoma Trial in Worldwide (XL092, Atezolizumab,

Recruiting
  • Neoplasm Malignant
  • +5 more
  • Duarte, California
  • +55 more
Aug 17, 2022

Mesothelioma, Glioblastoma, Renal Cell Carcinoma Trial in Korea, Republic of, Taiwan, United States (NGM707, NGM707 plus

Recruiting
  • Mesothelioma
  • +14 more
  • Los Angeles, California
  • +13 more
Aug 16, 2022

Renal Cell Carcinoma Trial in Houston (Ipilimumab, Nivolumab, Ciforadenant)

Not yet recruiting
  • Renal Cell Carcinoma
  • Houston, Texas
    M D Anderson Cancer Center
Aug 11, 2022

Pancreatic Cancer, Breast Cancer, Gastric Cancer Trial in Grand Rapids, New York, Houston (NGM438, Pembrolizumab)

Recruiting
  • Pancreatic Cancer
  • +15 more
  • Grand Rapids, Michigan
  • +2 more
Jul 18, 2022

Melanoma, NSCLC, Squamous Cell Carcinoma of Head and Neck Trial in United States (GEN-011, IL-2, Fludarabine)

Terminated
  • Melanoma
  • +8 more
  • GEN-011
  • +3 more
  • Gilbert, Arizona
  • +7 more
Jul 13, 2022

Brain Metastases, Renal Cell Carcinoma Trial in Houston (Nivolumab, Ipilimumab, Cabozantinib)

Not yet recruiting
  • Brain Metastases
  • Renal Cell Carcinoma
  • Houston, Texas
    M D Anderson Cancer Center
Jul 9, 2022

Oncology, Solid Tumor, Non Small Cell Lung Cancer Trial in United States (MRx0518, Pembrolizumab 25 MG/1 ML Intravenous Solution

Active, not recruiting
  • Oncology
  • +5 more
  • MRx0518
  • Pembrolizumab 25 MG/1 ML Intravenous Solution [KEYTRUDA]
  • Kansas City, Kansas
  • +4 more
Jul 5, 2022